CCL21、CXCL12及其受体在非霍奇金淋巴瘤中的表达及临床意义  

Expressions and clinical significance of CCL21,CXCL12 and their corresponding receptors in non-Hodgkin's lymphoma

作　　者：陆琴[1] 徐瑞容[2] 

机构地区：[1]海门市人民医院血液科,江苏省226100 [2]南通大学附属医院血液科

出　　处：《江苏医药》2017年第18期1302-1305,F0002,共5页Jiangsu Medical Journal

摘　　要：目的探讨趋化因子CCL21和CXCL12及其相应受体在非霍奇金淋巴瘤(NHL)中的表达及临床意义。方法回顾性分析68例NHL患者、34例淋巴结反应性增生患者及28例正常健康人群的临床资料,采用免疫组化法检测淋巴组织中CCL21、CXCL12及其受体的表达,ELISA法分析血浆中CCL21和CXCL12的表达,流式细胞术检测骨髓细胞中CXCR4、CCR7的表达。结果 CXCR4和CCL21在NHL多部位发生、最大标准摄取值(SUVmax)>9及侵袭性淋巴瘤中高表达;CXCL12和CCR7分别在SUVmax>9和侵袭性淋巴瘤中高表达。NHL患者化疗前CCL21、CXCL12、CXCR4和CCR7表达均高于淋巴结反应性增生患者和正常健康人群(P<0.05),而化疗后都有不同程度的降低。结论趋化因子CCL21和CXCL12及其受体表达与NHL侵袭、进展及预后密切相关。Objective To investigate the expressions and clinical significance of CCL21,CXCL12 and their corresponding receptors in non-Hodgkin＇s lymphoma（NHL）.Methods The clinical data of 68 patients with NHL,34 patients with reactive hyperplasia of lymph node and 28 healthy people were retrospectively analyzed.The expressions of CCL21,CXCL12 and their corresponding receptors in lymphoid tissues were detected by immunohistochemistry.The expressions of CXCL12 and CCL21in plasma were determined by ELISA,which of CXCR4 and CCR7in bone marrow cells were measured by flow cytometry.Results Both CXCR4 and CCL21 were highly expressed in multiple sites of tumor,SUVmax9 and aggressive lymphoma.While the higher expressions of CXCL12 and CCR7were found in SUVmax9and aggressive lymphoma,respectively.The expressions of CCL21,CXCL12,CXCR4 and CCR7 in the patients with NHL before chemotherapy were all significantly higher than those in the patients with reactive hyperplasia of lymph node and healthy people（P〈0.05）,and were decreased in different degrees after chemotherapy.Conclusion The expressions of CCL21,CXCL12 and their corresponding receptors are closely related to the invasion,progression and prognosis of NHL.

关 键 词：非霍奇金淋巴瘤 CCL21 CXCL12 CXCR4 CCR7 

分 类 号：R733[医药卫生—肿瘤]